Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Total 13F shares
-
122,106,524
-
Share change
-
+3,290,751
-
Total reported value
-
$4,828,909,500
-
Put/Call ratio
-
43%
-
Price per share
-
$39.54
-
Number of holders
-
337
-
Value change
-
+$122,331,434
-
Number of buys
-
170
-
Number of sells
-
167
Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2022
As of 30 Sep 2022,
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by
337 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
122,106,524 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, Artisan Partners Limited Partnership, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, GW&K Investment Management, LLC, and LOOMIS SAYLES & CO L P.
This page lists
340
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.